In the latest trading session, BioTelemetry (BEAT - Free Report) closed at $73.52, marking a +0.05% move from the previous day. This change outpaced the S&P 500's 0.94% loss on the day. Elsewhere, the Dow lost 0.87%, while the tech-heavy Nasdaq lost 1.18%.
Coming into today, shares of the heart monitoring device maker had gained 11.42% in the past month. In that same time, the Medical sector gained 6.01%, while the S&P 500 gained 8.01%.
Investors will be hoping for strength from BEAT as it approaches its next earnings release. On that day, BEAT is projected to report earnings of $0.42 per share, which would represent year-over-year growth of 31.25%. Our most recent consensus estimate is calling for quarterly revenue of $103.02 million, up 12.29% from the year-ago period.
It is also important to note the recent changes to analyst estimates for BEAT. Recent revisions tend to reflect the latest near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. BEAT is holding a Zacks Rank of #3 (Hold) right now.
Investors should also note BEAT's current valuation metrics, including its Forward P/E ratio of 41.28. This valuation marks a premium compared to its industry's average Forward P/E of 20.81.
We can also see that BEAT currently has a PEG ratio of 4.13. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. BEAT's industry had an average PEG ratio of 1.66 as of yesterday's close.
The Medical Services industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 108, which puts it in the top 43% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks. Com to follow all of these stock-moving metrics, and more, in the coming trading sessions.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
In the latest trading session, BioTelemetry (BEAT - Free Report) closed at $73.52, marking a +0.05% move from the previous day. This change outpaced the S&P 500's 0.94% loss on the day. Elsewhere, the Dow lost 0.87%, while the tech-heavy Nasdaq lost 1.18%.
Coming into today, shares of the heart monitoring device maker had gained 11.42% in the past month. In that same time, the Medical sector gained 6.01%, while the S&P 500 gained 8.01%.
Investors will be hoping for strength from BEAT as it approaches its next earnings release. On that day, BEAT is projected to report earnings of $0.42 per share, which would represent year-over-year growth of 31.25%. Our most recent consensus estimate is calling for quarterly revenue of $103.02 million, up 12.29% from the year-ago period.
It is also important to note the recent changes to analyst estimates for BEAT. Recent revisions tend to reflect the latest near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. BEAT is holding a Zacks Rank of #3 (Hold) right now.
Investors should also note BEAT's current valuation metrics, including its Forward P/E ratio of 41.28. This valuation marks a premium compared to its industry's average Forward P/E of 20.81.
We can also see that BEAT currently has a PEG ratio of 4.13. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. BEAT's industry had an average PEG ratio of 1.66 as of yesterday's close.
The Medical Services industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 108, which puts it in the top 43% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks. Com to follow all of these stock-moving metrics, and more, in the coming trading sessions.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Get the latest research report on BEAT - FREE